Investment Analysts’ Weekly Ratings Updates for Revolution Medicines (RVMD)

Several analysts have recently updated their ratings and price targets for Revolution Medicines (NASDAQ: RVMD):

• 5/21/2026 – Revolution Medicines is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $151.00 price target on the stock.
• 5/21/2026 – Revolution Medicines was upgraded by Sanford C. Bernstein to “hold”.
• 5/18/2026 – Revolution Medicines is now covered by Truist Financial Corporation. They set a “buy” rating and a $179.00 price target on the stock.
• 5/7/2026 – Revolution Medicines had its price target raised by Guggenheim to $205.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada to $165.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Revolution Medicines had its price target raised by Wedbush to $165.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – Revolution Medicines had its price target raised by Piper Sandler to $172.00. They now have an “overweight” rating on the stock.
• 4/27/2026 – Revolution Medicines was upgraded by Truist Financial Corporation to “strong-buy”.
• 4/22/2026 – Revolution Medicines had its “buy” rating reaffirmed by HC Wainwright.
• 4/21/2026 – Revolution Medicines had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/20/2026 – Revolution Medicines had its “buy” rating reaffirmed by Stifel Nicolaus.
• 4/14/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Evercore Inc.
• 4/14/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Wedbush.

Insider Transactions at Revolution Medicines

In other news, COO Margaret A. Horn sold 4,583 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $455,916.84. Following the completion of the sale, the chief operating officer directly owned 157,570 shares in the company, valued at approximately $15,675,063.60. The trade was a 2.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Xiaolin Wang sold 2,010 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $199,954.80. Following the sale, the insider owned 116,063 shares of the company’s stock, valued at $11,545,947.24. This represents a 1.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 184,592 shares of company stock worth $24,499,532. Corporate insiders own 8.20% of the company’s stock.

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.